Format
Sort by
Items per page

Send to

Choose Destination

Selected items

Items: 20

1.

Technology evaluation: ipilimumab, Medarex/Bristol-Myers Squibb.

Morse MA.

Curr Opin Mol Ther. 2005 Dec;7(6):588-97.

PMID:
16370382
2.

Entecavir (Bristol-Myers Squibb).

Billich A.

Curr Opin Investig Drugs. 2001 May;2(5):617-21. Review.

PMID:
11569933
3.

BMS-561392. Bristol-Myers Squibb.

Grootveld M, McDermott MF.

Curr Opin Investig Drugs. 2003 May;4(5):598-602. Review.

PMID:
12833656
4.

Cetuximab (Imclone/Merck/Bristol-Myers Squibb).

Kies MS, Harari PM.

Curr Opin Investig Drugs. 2002 Jul;3(7):1092-100. Review.

PMID:
12186273
5.

Case study: technology initiative led to advanced lead optimization screening processes at Bristol-Myers Squibb, 2004-2009.

Zhang L, Cvijic ME, Lippy J, Myslik J, Brenner SL, Binnie A, Houston JG.

Drug Discov Today. 2012 Jul;17(13-14):733-40. doi: 10.1016/j.drudis.2012.02.012. Epub 2012 Mar 7. Review.

PMID:
22425710
6.

BMS-275291. Bristol-Myers Squibb.

Poulaki V.

Curr Opin Investig Drugs. 2002 Mar;3(3):500-4. Review.

PMID:
12054103
7.

HIV/AIDS in African children: the Bristol-Myers Squibb Foundation and Baylor response.

Damonti J, Doykos P, Wanless RS, Kline M.

Health Aff (Millwood). 2012 Jul;31(7):1636-42. doi: 10.1377/hlthaff.2012.0425.

8.

Anti-MRSA cephalosporins Bristol-Myers Squibb.

Johnson AP.

Curr Opin Investig Drugs. 2001 Feb;2(2):205-8. Review.

PMID:
11816831
9.

Omapatrilat. Bristol-Myers Squibb.

Tabrizchi R.

Curr Opin Investig Drugs. 2001 Oct;2(10):1414-22. Review.

PMID:
11890357
10.

Case study: impact of technology investment on lead discovery at Bristol-Myers Squibb, 1998-2006.

Houston JG, Banks MN, Binnie A, Brenner S, O'Connell J, Petrillo EW.

Drug Discov Today. 2008 Jan;13(1-2):44-51. doi: 10.1016/j.drudis.2007.11.004. Epub 2008 Jan 3. Review.

PMID:
18190863
11.

BMS-193884 and BMS-207940 Bristol-Myers Squibb.

Hulpke-Wette M, Buchhorn R.

Curr Opin Investig Drugs. 2002 Jul;3(7):1057-61. Review.

PMID:
12186267
12.

Technology evaluation: abatacept, Bristol-Myers Squibb.

Dumont FJ.

Curr Opin Mol Ther. 2004 Jun;6(3):318-30. Review.

PMID:
15264435
14.

BMS-204352 (Bristol Myers Squibb).

Mackay KB.

Curr Opin Investig Drugs. 2001 Jun;2(6):820-3. Review.

PMID:
11572663
15.

Deal watch: Bristol-Myers Squibb invests in cancer antibody that targets the innate immune system.

[No authors listed]

Nat Rev Drug Discov. 2011 Aug 31;10(9):648. doi: 10.1038/nrd3537. No abstract available.

PMID:
21878969
16.

BMS-232632 (Novartis/Bristol-Myers Squibb).

Witherell G.

Curr Opin Investig Drugs. 2001 Mar;2(3):340-7.

PMID:
11575702
17.

BMS-310705 Bristol-Myers Squibb/GBF.

Kolman A.

Curr Opin Investig Drugs. 2004 Dec;5(12):1292-7. Review.

PMID:
15648951
18.

Ravuconazole Eisai/Bristol-Myers Squibb.

Arikan S, Rex JH.

Curr Opin Investig Drugs. 2002 Apr;3(4):555-61. Review.

PMID:
12090723
19.

Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients. A randomized, double-blind, controlled trial. Bristol-Myers Squibb Stavudine/019 Study Group.

Spruance SL, Pavia AT, Mellors JW, Murphy R, Gathe J Jr, Stool E, Jemsek JG, Dellamonica P, Cross A, Dunkle L.

Ann Intern Med. 1997 Mar 1;126(5):355-63.

PMID:
9054279

Supplemental Content

Support Center